MY129008A - Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotheraphy - Google Patents

Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotheraphy

Info

Publication number
MY129008A
MY129008A MYPI20012470A MY129008A MY 129008 A MY129008 A MY 129008A MY PI20012470 A MYPI20012470 A MY PI20012470A MY 129008 A MY129008 A MY 129008A
Authority
MY
Malaysia
Prior art keywords
vip
radiolabeled
receptor
vasoactive intestinal
agent
Prior art date
Application number
Inventor
Anand C Burman
Prasad Sudhanand
Mukherjee Rama
Dutt Sarjana
Sharma Rajan
Ahuja Rinku
Anil K Mishra
Lazar T Mathew
Original Assignee
Dabur Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/629,632 external-priority patent/US6608174B1/en
Application filed by Dabur Res Foundation filed Critical Dabur Res Foundation
Publication of MY129008A publication Critical patent/MY129008A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

THE PRESENT INVENTION ENCOMPASES RADIOLABELED PEPTIDE ANALOGS OF VASOACTIVE INTESTINAL PEPTIDE (VIP) LABELED WITH A RADIONUCLIDE USEFUL FOR IMAGING TARGET SITES WITHIN MAMMALIAN LIVING SYSTEMS. THE INVENTION PARTICULARLY PROVIDES RADIOLABELED VIP DERIVATIVES THAT BIND SELECTIVELY TO THE VIP RECEPTOR ON TARGET CELLS.SPECIFICALLY, THE INVENTION RELATES TO THE RADIOLABELING OF VIP-RECEPTOR SPECIFIC AGENTS AND THEIR SUBSEQUENTS USE FOR RADIODIAGNOSTIC AND RADIOTHERAPEUTIC PURPOSES. THE INVENTION ENCOMPASSES METHODS FOR RADIOLABELING THESE PEPTIDES WITH RADIO-NUCLIDES AND THE USE OF THESE PEPTIDES AS SCINTIGRAPHIC IMAGING AGENTS. THE RADIOLABELED VIP DERIVATIVES OF THE PRESENT INVENTION EXHIBIT PHARMACOLOGICAL ACTIVITY AND THEREFORE ARE USEFUL AS EITHER IMAGING AGENT FOR VISUALIZATION OF VIP-RECEPTOR POSITIVE TUMORS AND MATESTASES, AS A RADIODIAGNOSTIC AGENT OR AS A RADIO- THERAPEUTIC AGENT FOR THE TREATMENT OF SUCH TUMORS IN VIVO BY SPECIFICALLY TARGETING THE CYTOTOXIC RADIONUCLIDE SELECTIVELY TO THE TUMOR SITE IN MAMMALIAN LIVING SYSTEMS.(FIG.1)
MYPI20012470 2000-07-31 2001-05-24 Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotheraphy MY129008A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/629,632 US6608174B1 (en) 2000-02-18 2000-07-31 Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy

Publications (1)

Publication Number Publication Date
MY129008A true MY129008A (en) 2007-03-30

Family

ID=37515842

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20012470 MY129008A (en) 2000-07-31 2001-05-24 Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotheraphy

Country Status (3)

Country Link
AR (1) AR030223A1 (en)
MY (1) MY129008A (en)
TW (1) TWI288751B (en)

Also Published As

Publication number Publication date
TWI288751B (en) 2007-10-21
AR030223A1 (en) 2003-08-13

Similar Documents

Publication Publication Date Title
Kiess et al. Prostate-specific membrane antigen as a target for cancer imaging and therapy
Miao et al. In vivo evaluation of 188Re‐labeled alpha‐melanocyte stimulating hormone peptide analogs for melanoma therapy
Smith et al. Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN [7-14] NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells
Baidoo et al. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues
Gali et al. Synthesis, characterization, and labeling with 99mTc/188Re of peptide conjugates containing a dithia-bisphosphine chelating agent
Hoffman et al. Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells
Bullok et al. Characterization of novel histidine-tagged Tat-peptide complexes dual-labeled with 99mTc-tricarbonyl and fluorescein for scintigraphy and fluorescence microscopy
Xu et al. 99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen
EP3486249B1 (en) 99mtc-edda/hynic-ipsma as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen
Koumarianou et al. 44Sc-DOTA-BN [2-14] NH2 in comparison to 68Ga-DOTA-BN [2-14] NH2 in pre-clinical investigation. Is 44Sc a potential radionuclide for PET?
Jackson et al. 64Cu-NO2A-RGD-Glu-6-Ahx-BBN (7-14) NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer
ES2960729T3 (en) 177 Lu-dota-hynic-ipsma as a therapeutic radiopharmaceutical targeting prostate-specific membrane antigen
Maina et al. Targeting prostate cancer with radiolabelled bombesins
MX9707426A (en) Radiolabeled peptides for diagnosis and therapy.
Abiraj et al. Tetraamine‐derived bifunctional chelators for technetium‐99m labelling: Synthesis, bioconjugation and evaluation as targeted SPECT imaging probes for GRP‐receptor‐positive tumours
M Rey Radiometal complexes in molecular imaging and therapy
Guo et al. Melanoma targeting property of a Lu-177-labeled lactam bridge-cyclized alpha-MSH peptide
Craft et al. In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer
KR20070106731A (en) Radiolabeled gallium complexes, methods for synthesis and use for pet imaging of egfr expression in malignant tumors
CA2287838C (en) Radionuclide associated with nucleotide polyphosphate as tumor imaging agents
Maina et al. [99m Tc] Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results
AU2000263935A1 (en) Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy
Ferro-Flores et al. Radiolabeled protein-inhibitor peptides with rapid clinical translation towards imaging and therapy
Zheng et al. Comparison of biological properties of 111In-labeled dimeric cyclic RGD peptides
Miao et al. Therapeutic efficacy of a 177Lu-labeled DOTA conjugated α-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model